U. Bruntsch
Impact in
- Otorhinolaryngology top 5%
- Head and Neck Cancer Studies
- Oncology top 10%
- Cancer Treatment and Pharmacology
Papers in
- Co-authors
- W. M. Gallmeier (21 shared papers)M. Clavel (5 shared papers)Marlies Peters (1 shared paper)Cornelis J.A. Punt (1 shared paper)Joseph Boni (1 shared paper)J. Renard (7 shared papers)J. Wanders (8 shared papers)Herbert M. Pinedo (5 shared papers)
- Journals
- European Journal of Cancer (5 papers)Annals of Oncology (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)Investigational New Drugs (2 papers)Supportive Care in Cancer (2 papers)
- Partner nations
- GermanySwitzerlandBelgium
In The Last Decade
U. Bruntsch
50 papers receiving 775 citations
Peers
Comparison fields: 5 of 78
- Otorhinolaryngology 68
- Oncology 256
- Pathology and Forensic Medicine 88
- Hematology 55
- Complementary and alternative medicine 35
Countries citing papers authored by U. Bruntsch
This map shows the geographic impact of U. Bruntsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Bruntsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Bruntsch more than expected).
Fields of papers citing papers by U. Bruntsch
This network shows the impact of papers produced by U. Bruntsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Bruntsch. The network helps show where U. Bruntsch may publish in the future.
Co-authors
The 25 scholars most cited alongside U. Bruntsch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1994 | 108 | |
| 2 | 2003 | 95 | |
| 3 | 1987 | 91 | |
| 4 | 1991 | 90 | |
| 5 | 1998 | 48 | |
| 6 | 2000 | 43 | |
| 7 | 1985 | 24 | |
| 8 | 1984 | 23 | |
| 9 | Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. | 2000 | 22 |
| 10 | 1994 | 21 | |
| 11 | 1996 | 20 | |
| 12 | 1984 | 20 | |
| 13 | 1984 | 18 | |
| 14 | Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. | 1996 | 16 |
| 15 | 1998 | 15 | |
| 16 | 1993 | 15 | |
| 17 | 1986 | 13 | |
| 18 | 1997 | 13 | |
| 19 | 1992 | 12 | |
| 20 | 1994 | 10 |
About U. Bruntsch
U. Bruntsch is a scholar working on Oncology, Surgery, Molecular Biology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 55 papers that have together received 821 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (7 papers), Nausea and vomiting management (6 papers), Cancer Treatment and Pharmacology (6 papers), Lymphoma Diagnosis and Treatment (6 papers), Lung Cancer Treatments and Mutations (5 papers), Neutropenia and Cancer Infections (4 papers), Cancer therapeutics and mechanisms (4 papers) and Pharmacological Effects and Toxicity Studies (4 papers). The work is most often cited by research in Otorhinolaryngology (68 citations), Oncology (256 citations), Pathology and Forensic Medicine (88 citations), Hematology (55 citations) and Complementary and alternative medicine (35 citations). U. Bruntsch has collaborated with scholars based in Germany, Switzerland and Belgium. Frequent co-authors include W. M. Gallmeier, M. Clavel, Marlies Peters, Cornelis J.A. Punt, Joseph Boni, J. Renard, J. Wanders, Herbert M. Pinedo, Jaap Verweij and M. van Glabbeke. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Cancer Chemotherapy and Pharmacology, Investigational New Drugs and Supportive Care in Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.